News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
After making significant investments in its personalized immunocellullar manufacturing technology, Prima BioMed is looking to scale up the platform as the company’s lead product enters Phase II trials.
Novo Nordisk has invested 550m Danish Kroner ($100m) to expand a purification plant in Denmark for its diabetes biodrug pipeline.
When Frank Sinatra sang "If you can make it there, you can make it anywhere" in New York, New York he probably wasn't talking about biopharmaceutical production.
The US FDA says that it “becomes concerned” when excess volume in an injectable vial is greater or less than what the US Pharmacopeia (USP) recommends without proper justification, according to new draft guidance.
Caisson Biotech has licensed its drug-extending technology for injectables to Novo Nordisk.